secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628280-24-035974
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen reports Q2 net loss $0.04/sh; advances OCU400 Phase 3 trial, raises $32.6M
--------------------------------------------------------------------------------

- Net loss per share $0.04 in Q2 2024 versus $0.10 in Q2 2023; total operating expenses $16.6M, down from $24.0M.
- Cash, equivalents, restricted cash $16.0M at June 30, 2024, down from $39.5M at Dec 31, 2023.
- Subsequent to quarter end, closed public offering with net proceeds $32.6M, extending cash runway into Q3 2025.
- Actively dosing patients in OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa; FDA approved expanded access program.
- OCU410 Phase 2 initiated for geographic atrophy; OCU410ST high-dose dosing; OCU200 clinical hold discussions ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024035974/0001628280-24-035974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024035974/ocgn-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer